Liver Positron Emission Tomography (PET) Study of Non Alcoholic Fatty Liver Disease

NCT ID: NCT00949403

Last Updated: 2020-06-22

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: EARLY_PHASE1
• Total Enrollment: 9 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2010-07-31
• Study Completion Date: 2011-01-19

Brief Summary

The purpose of this study is to evaluate how the liver receives and uses fats for energy. This will help the investigators further understand the physical and chemical processes responsible for Non-Alcoholic Fatty Liver Disease (NAFLD) in overweight females with or without NAFLD who are scheduled to undergo gastric bypass surgery.

Detailed Description

This study involves a multidisciplinary approach that will address the metabolic mechanisms responsible for Non-alcoholic Fatty Liver Disease (NAFLD) in humans. Nonalcoholic fatty liver disease (NAFLD) has become an important public health problem in many industrialized countries because of its high prevalence, potential progression to severe liver disease, and association with cardiometabolic abnormalities, including diabetes, the metabolic syndrome, dilated cardiomyopathy, and coronary heart disease. Although obesity is an important risk factor for NAFLD many obese persons have minimal or no steatosis. The mechanism responsible for the pathogenesis of steatosis is not known, but must involve one or more of the following:

1. Increased hepatic fatty acid (FA) delivery

2. Decreased hepatic FA oxidation

3. Increased de novo lipogenesis (DNL)

4. Inadequate hepatic triglyceride secretion

We hypothesize that alterations in all of these metabolic processes are involved in the pathogenesis of NAFLD. However, a comprehensive evaluation of these factors in individual cohorts of subjects has never been performed, and the ability to measure hepatic FA oxidation in vivo in human subjects has not been available.

The following Specific Aims will be evaluated in obese women with and without NAFLD, who are scheduled for bariatric surgery:

1. Determine hepatic FA uptake and oxidation by using novel PET techniques in combination with measurements of DNL using stable isotope tracers and by assessing liver tissue FA oxidative capacity by evaluating gene expression of FA oxidative enzymes and mitochondrial content.

2. Determine hepatic fatty acid delivery by using stable isotope tracers to assess the rate of free FA (FFA) release into plasma and cellular biology methods to determine the expression and protein content of the major tissue FA transporter (CD36).

3. Determine hepatic very-low-density lipoprotein TG (VLDL-TG) secretion rate by using stable isotope tracers.

4. Determine liver histology and factors involved in inflammation and fibrosis by using routine staining and immunohistochemistry.

Conditions

Fatty Liver

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: NONE

Study Groups

Obese Females (pre-bariatric surgery)

Twenty obese females (18-45 years of age, BMI \> or equal to 45) who are scheduled to undergo bariatric surgery at Barnes-Jewish Hospital will be screened for enrollment over 2 years. They will be imaged with PET/CT and radiopharmaceuticals C-11 Acetate and C-11 Palmitate will be injected.

Group Type: EXPERIMENTAL

Radio pharmaceuticals C-11 Acetate, and C-11 Palmitate

Intervention Type: DRUG

injection of C-11 Palmitate and C-11 Acetate during PET/CT to determine Liver metabolism

Interventions

Radio pharmaceuticals C-11 Acetate, and C-11 Palmitate

injection of C-11 Palmitate and C-11 Acetate during PET/CT to determine Liver metabolism

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Obese females with a BMI of greater then or equal to 45.
• Age range between 18-45 years.
• Patients undergoing bariatric surgery at Barnes-Jewish Hospital-St.Louis,MO.

Exclusion Criteria

• Any prior history or evidence of liver disease other than Non-Alcoholic Fatty liver Disease, severe hypertriglyceridemia and diabetes mellitis.
• Consumed greater then or equal to 20 grams of alcohol per day.
• Taking medications that are known to cause hepatic steatosis & liver damage.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 45 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

Barnes-Jewish Hospital

OTHER

Sponsor Role: collaborator

Washington University School of Medicine

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Robert J Gropler, MD

Role: PRINCIPAL_INVESTIGATOR

PI

Locations

Washington University School of Medicine

St Louis, Missouri, United States

Washington University

St Louis, Missouri, United States

Countries

United States

Other Identifiers

09-0621

Identifier Type: -

Identifier Source: org_study_id